EGFR and neoplasm: Furthermore, generating TKI-resistance in-vitro or in-vivo in EGFR mutant cancer cell lines engineered to have loss of RB expression did not yield resistant cells/tumours with acquisition of NE marker expression or SCLC morphology (Supplementary Fig. 6b,c).